Thousand Oaks-based Amgen and San Diego-based Illumina are in an agreement to develop and commercialize a test for metastatic colorectal cancer, Illumina said late Wednesday. Illumina said the test will use its MiSeqDx instrument to develop a test platform which can identify patients who would be appropriate to receive Vectibix, Amgen's anti-EGFR monocolonal antibody--which is used for treating colorectal cancer. Financial terms of the deal were not disclosed.
Top NewsThursday, January 16, 2014
Amgen, Illumina In Diagnostic Test Deal